Boston Scientific Comprehensive Income 2010-2024 | BSX
Boston Scientific comprehensive income from 2010 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
- Boston Scientific comprehensive income for the quarter ending December 31, 2024 was $0.275B, a 461.22% increase year-over-year.
- Boston Scientific comprehensive income for 2024 was $0.275B, a 461.22% increase from 2023.
- Boston Scientific comprehensive income for 2023 was $0.049B, a 81.78% decline from 2022.
- Boston Scientific comprehensive income for 2022 was $0.269B, a 2.28% increase from 2021.
| Boston Scientific Annual Comprehensive Income (Millions of US $) |
|
|---|---|
| 2024 | $275 |
| 2023 | $49 |
| 2022 | $269 |
| 2021 | $263 |
| 2020 | $207 |
| 2019 | $270 |
| 2018 | $33 |
| 2017 | $-59 |
| 2016 | $1 |
| 2015 | $88 |
| 2014 | $144 |
| 2013 | $106 |
| 2012 | $-33 |
| 2011 | $-138 |
| 2010 | $-129 |
| 2009 | $-43 |
| Boston Scientific Quarterly Comprehensive Income (Millions of US $) |
|
|---|---|
| 2024-12-31 | $275 |
| 2024-09-30 | $-128 |
| 2024-06-30 | $164 |
| 2024-03-31 | $132 |
| 2023-12-31 | $49 |
| 2023-09-30 | $231 |
| 2023-06-30 | $208 |
| 2023-03-31 | $178 |
| 2022-12-31 | $269 |
| 2022-09-30 | $532 |
| 2022-06-30 | $433 |
| 2022-03-31 | $222 |
| 2021-12-31 | $263 |
| 2021-09-30 | $238 |
| 2021-06-30 | $237 |
| 2021-03-31 | $254 |
| 2020-12-31 | $207 |
| 2020-09-30 | $151 |
| 2020-06-30 | $131 |
| 2020-03-31 | $168 |
| 2019-12-31 | $270 |
| 2019-09-30 | $138 |
| 2019-06-30 | $78 |
| 2019-03-31 | $87 |
| 2018-12-31 | $33 |
| 2018-09-30 | $25 |
| 2018-06-30 | $-16 |
| 2018-03-31 | $-128 |
| 2017-12-31 | $-59 |
| 2017-09-30 | $-51 |
| 2017-06-30 | $-53 |
| 2017-03-31 | $-46 |
| 2016-12-31 | $1 |
| 2016-09-30 | $-99 |
| 2016-06-30 | $-70 |
| 2016-03-31 | $35 |
| 2015-12-31 | $88 |
| 2015-09-30 | $81 |
| 2015-06-30 | $104 |
| 2015-03-31 | $142 |
| 2014-12-31 | $144 |
| 2014-09-30 | $110 |
| 2014-06-30 | $42 |
| 2014-03-31 | $72 |
| 2013-12-31 | $106 |
| 2013-09-30 | $56 |
| 2013-06-30 | $82 |
| 2013-03-31 | $45 |
| 2012-12-31 | $-33 |
| 2012-09-30 | $-112 |
| 2012-06-30 | $-87 |
| 2012-03-31 | $-79 |
| 2011-12-31 | $-138 |
| 2011-09-30 | $-132 |
| 2011-06-30 | $-123 |
| 2011-03-31 | $-119 |
| 2010-12-31 | $-129 |
| 2010-09-30 | |
| 2010-06-30 | |
| 2010-03-31 | $-18 |
| 2009-12-31 | $-43 |
| 2009-09-30 | |
| 2009-06-30 | |
| 2009-03-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $149.209B | $16.747B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $230.058B | 28.41 |
| Stryker (SYK) | United States | $142.084B | 30.54 |
| EssilorLuxottica (ESLOY) | France | $131.854B | 0.00 |
| Medtronic (MDT) | Ireland | $115.249B | 16.83 |
| Haleon (HLN) | United Kingdom | $46.488B | 26.39 |
| Lonza Group Ag (LZAGY) | Switzerland | $44.527B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $36.909B | 17.98 |
| Agilent Technologies (A) | United States | $33.351B | 22.03 |
| ResMed (RMD) | United States | $32.876B | 25.32 |
| Terumo (TRUMY) | Japan | $27.805B | 39.54 |
| Koninklijke Philips (PHG) | Netherlands | $23.874B | 17.05 |
| Zimmer Biomet Holdings (ZBH) | United States | $22.530B | 14.15 |
| Insulet (PODD) | United States | $18.442B | 78.86 |
| Baxter (BAX) | United States | $17.557B | 12.63 |
| Sunny Optical Technology (SNPTF) | China | $12.864B | 0.00 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.403B | 0.00 |
| Demant (WILYY) | Denmark | $8.048B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.822B | 23.62 |
| Lantheus Holdings (LNTH) | United States | $6.684B | 16.43 |
| Prestige Consumer Healthcare (PBH) | United States | $4.259B | 20.32 |
| Perrigo (PRGO) | Ireland | $3.826B | 10.95 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| ICU Medical (ICUI) | United States | $3.405B | 29.11 |
| Haemonetics (HAE) | United States | $3.193B | 15.02 |
| Envista Holdings (NVST) | United States | $2.972B | 23.64 |
| QuidelOrtho (QDEL) | United States | $2.359B | 19.76 |
| GN Store Nord (GNNDY) | Denmark | $2.336B | 15.74 |
| LeMaitre Vascular (LMAT) | United States | $1.893B | 43.25 |
| Neogen (NEOG) | United States | $1.881B | 21.67 |
| AtriCure (ATRC) | United States | $1.577B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.462B | 14.08 |
| Kestra Medical Technologies (KMTS) | $1.234B | 0.00 | |
| InMode (INMD) | Israel | $1.234B | 10.31 |
| Green Thumb Industries (GTBIF) | United States | $1.233B | 19.37 |
| BioLife Solutions (BLFS) | United States | $1.073B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.865B | 13.27 |
| Evolus (EOLS) | United States | $0.765B | 0.00 |
| Owens & Minor (OMI) | United States | $0.698B | 5.94 |
| CeriBell (CBLL) | United States | $0.689B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.601B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.562B | 0.00 |
| Valneva SE (VALN) | France | $0.545B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.478B | 20.71 |
| Omeros (OMER) | United States | $0.476B | 0.00 |
| Surmodics (SRDX) | United States | $0.436B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.433B | 0.00 |
| SNDL (SNDL) | Canada | $0.371B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.354B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.329B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.302B | 0.00 |
| ZimVie (ZIMV) | United States | $0.301B | 18.00 |
| Viemed Healthcare (VMD) | United States | $0.288B | 26.00 |
| Sanara MedTech (SMTI) | United States | $0.275B | 0.00 |
| Cerus (CERS) | United States | $0.258B | 0.00 |
| Quanterix (QTRX) | United States | $0.252B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.252B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.247B | 43.90 |
| Verano Holdings (VRNOF) | United States | $0.233B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.184B | 14.19 |
| Biote (BTMD) | United States | $0.182B | 4.16 |
| Brainsway (BWAY) | Israel | $0.178B | 55.71 |
| TriSalus Life Sciences (TLSI) | United States | $0.168B | 0.00 |
| High Tide (HITI) | Canada | $0.153B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.144B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.140B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.128B | 0.00 |
| Jin Medical (ZJYL) | China | $0.116B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.112B | 13.99 |
| Quipt Home Medical (QIPT) | United States | $0.100B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.087B | 0.00 |
| Fonar (FONR) | United States | $0.087B | 12.18 |
| MacroGenics (MGNX) | United States | $0.080B | 0.00 |
| Veru (VERU) | United States | $0.072B | 0.00 |
| Zynex (ZYXI) | United States | $0.067B | 24.44 |
| United Health Products (UEEC) | United States | $0.066B | 0.00 |
| Exagen (XGN) | United States | $0.064B | 0.00 |
| InterCure (INCR) | Israel | $0.064B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.059B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.055B | 0.00 |
| Apyx Medical (APYX) | United States | $0.052B | 0.00 |
| Modular Medical (MODD) | United States | $0.044B | 0.00 |
| ImmuCell (ICCC) | United States | $0.043B | 0.00 |
| United-Guardian (UG) | United States | $0.041B | 12.66 |
| Rockwell Medical (RMTI) | United States | $0.038B | 56.50 |
| Safety Shot (SHOT) | United States | $0.027B | 0.00 |
| INLIF (INLF) | $0.021B | 0.00 | |
| Nephros (NEPH) | United States | $0.018B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.015B | 0.00 |
| Flora Growth (FLGC) | United States | $0.012B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.006B | 0.00 |
| Agape ATP (ATPC) | $0.005B | 0.00 | |
| IM Cannabis (IMCC) | Canada | $0.003B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |